Stock Analiz

INCY vs CRL stock comparison

Incyte vs. Charles River Laboratories International · data as of November 13, 2026

Incyte (INCY) has a market value of about $24.7B, Charles River Laboratories International (CRL) about $16.2B. Over their latest twelve months Incyte had revenue of $6.0B and Charles River Laboratories International $4.0B.

On our five checks Incyte scores higher: 2.8 out of 5 (average) against 1.2 (weak).

By area, the stronger company is Incyte on future growth; Incyte on track record; Incyte on financial health; Charles River Laboratories International on shareholder returns.

Incyte is cheaper on earnings (P/E 61.7 vs. 367.4).

Incyte leads on 16 of the compared lines and Charles River Laboratories International on 3.

Side by side

INCYCRL
Size and price
Market cap$24.7B$16.2B
Share price$120.97$337.97
Score
Overall score (of 5)2.81.2
Value00
Future growth41
Track record30
Financial health52
Shareholder returns23
Valuation
P/E (TTM)61.7367.4
Forward P/E15.126.7
Price / free cash flow36.340.5
Price / sales4.14.1
EV / EBITDA29.542.4
PEG——
DCF value vs. price−48%−76%
Business
Revenue$6.0B$4.0B
Net income$403M$40M
Free cash flow$680M$400M
Net margin6.7%1.0%
Gross margin (5-yr avg.)93.5%—
ROIC (5-yr avg.)10.6%5.6%
Growth
Revenue growth (1 yr)21.2%-0.9%
Revenue growth (5 yrs, per year)14.0%6.6%
EPS growth (5 yrs, per year)——
Balance sheet and payouts
Net cash (cash minus debt)—-$2.7B
Dividend yieldNoneNone
Shareholder yield0.0%2.2%
Analysts
Upside to average target+9%+4%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: INCY TTM to September 30, 2026, CRL TTM to September 26, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Incyte or Charles River Laboratories International?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Incyte scores 2.8 out of 5 and Charles River Laboratories International 1.2; the table shows where each one is stronger.

Is Incyte cheaper than Charles River Laboratories International?

On trailing earnings, Incyte trades at a P/E of 61.7 and Charles River Laboratories International at 367.4, so Incyte is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Incyte or Charles River Laboratories International?

Over five years Incyte grew revenue about 14.0% a year and Charles River Laboratories International about 6.6% a year.

Full Incyte analysis → Full Charles River Laboratories International analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.